Liver Safety Warning for Tavneos (avacopan)

Introduction

In April 2026, the FDA issued a safety communication after post-marketing surveillance identified cases of serious, drug-induced liver injury (DILI) in patients treated with Tavneos (avacopan). Approved to treat severe active ANCA-associated vasculitis (GPA and MPA), Tavneos was designed to replace long-term, high-dose steroids. While the drug remains highly effective, this new data suggests that the liver risk is more significant than initially observed in clinical trials, requiring a more aggressive monitoring protocol for US patients this year.

The Nature of the Liver Risk

The reported cases involve significant elevations in liver enzymes (ALT and AST) and bilirubin, with some patients progressing to clinical jaundice.

• The Timing: Most injuries occurred within the first 2 to 6 months of starting treatment.
• The Mechanism: While the exact cause is still being studied, the injury appears to be an idiosyncratic (unpredictable) reaction to the molecule itself rather than a dose-dependent toxicity.

The April 2026 “Enhanced Monitoring” Protocol

US rheumatologists and nephrologists are now being advised to implement a “Strict Zero-Tolerance” monitoring schedule for Tavneos:

1. Bi-Weekly Testing: For the first 3 months of therapy, liver function tests (LFTs) should be performed every two weeks, moving to monthly for the following 3 months.
2. Immediate Discontinuation: If transaminases (ALT/AST) exceed 3x the upper limit of normal, the FDA now recommends pausing Tavneos immediately until the cause is determined.
3. Patient Education: Patients must be taught to self-screen daily for the “Yellow Flag” symptoms of liver stress.

Quick Clinical FAQ (April 2026)

1. Should I stop taking Tavneos? No, unless you are instructed by your doctor or notice signs of liver injury. Abruptly stopping treatment can cause a vasculitis “flare.”
2. What are the ‘Yellow Flag’ symptoms? Dark-colored urine (tea-colored), yellowing of the skin or eyes (jaundice), unusual fatigue, and pain in the upper right side of your stomach.
3. Does this mean I have to go back on Prednisone? If Tavneos must be stopped, your doctor will likely bridge you with steroids or other immunosuppressants (like Rituxan) to keep your vasculitis in check.
4. Can I drink alcohol while on Tavneos? In 2026, US clinicians are advising strict alcohol avoidance, as even moderate drinking can make liver monitoring results harder to interpret.
5. Is the damage permanent? In most reported cases, liver enzymes returned to normal levels after the medication was discontinued.
6. Are certain people at higher risk? Patients with pre-existing liver conditions or those taking other potentially hepatotoxic drugs (like certain antibiotics or high-dose NSAIDs) should be monitored even more closely.
7. Why wasn’t this in the original label? Rare side effects often only appear when a drug moves from a small clinical trial to “real-world” use by thousands of people.
8. Will Tavneos be recalled? As of April 2026, a recall is not expected. The benefit of avoiding steroid-induced complications still outweighs the liver risk for most patients, provided monitoring is strict.
9. What if my LFTs are just slightly elevated? Your doctor may repeat the test more frequently. Small fluctuations are common, but the new 2026 guidelines focus on significant spikes.
10. Can DrGuide’s AI Pharmacist track my lab results? Yes! Our AI can help you log your bi-weekly LFT results and alert you if your numbers are trending toward the 2026 FDA “Pause Zone.”